Keyphrases
Drug Response
100%
Diffuse Intrinsic Pontine Glioma
100%
Pediatric Glioma
100%
Drug Resistance
100%
Drug Efflux
100%
Drug Transporters
100%
Glioma Cells
50%
Multidrug Resistance Protein 1 (MDR1)
50%
Tumor
33%
Chemotherapy
33%
Drug Delivery
33%
P-glycoprotein (P-gp)
33%
BCRP1
33%
Clinical Trials
16%
Cancer Mortality
16%
Radiotherapy
16%
Tumor Tissue
16%
Resistance Mechanisms
16%
Drug Sensitivity
16%
Glioma Patients
16%
Melphalan
16%
Blood-brain Barrier
16%
Cancer Causes
16%
Per Se
16%
Glioma Tumor
16%
Glioma
16%
Mitoxantrone
16%
Treatment Failure
16%
Primary Glioma
16%
Drug Screen
16%
Novel Targeted Agents
16%
Tumor Expression
16%
Bortezomib
16%
Vandetanib
16%
Tumor Vasculature
16%
Confounding Effect
16%
In Vitro Cytotoxicity
16%
Doxorubicine
16%
Medicine and Dentistry
Pediatrics
100%
In Vitro
100%
Drug Response
100%
Ganglioglioma
100%
Pontine Glioma
100%
Drug Resistance
100%
Effusion
100%
Neoplasm
66%
Glioma Cell
50%
Multidrug Resistance Associated Protein 1
50%
Chemotherapy
33%
Malignant Neoplasm
16%
Clinical Trial
16%
Radiation Therapy
16%
Doxorubicin
16%
Drug Sensitivity
16%
Blood Brain Barrier
16%
Cytotoxicity
16%
Carmustine
16%
Mitoxantrone
16%
Tumor Vascularization
16%
Bortezomib
16%
Melphalan
16%
Vandetanib
16%
Pharmacology, Toxicology and Pharmaceutical Science
Pontine Glioma
100%
Glioma
100%
Drug Resistance
100%
Effusion
100%
Neoplasm
66%
Multidrug Resistance Associated Protein 1
50%
Chemotherapy
33%
Clinical Trial
16%
Malignant Neoplasm
16%
Doxorubicin
16%
Melphalan
16%
Carmustine
16%
Vandetanib
16%
Tumor Vascularization
16%
Mitoxantrone
16%
Bortezomib
16%
Cytotoxicity
16%
Blood-Brain Barrier
16%
Neuroscience
In Vitro
100%
Drug Resistance
100%
Multidrug Resistance Associated Protein 1
100%
Radiation Therapy
33%
Blood Brain Barrier
33%
Cytotoxicity
33%
Melphalan
33%
Bortezomib
33%
Vandetanib
33%
Mitoxantrone
33%
Doxorubicin
33%